Best Life Sciences Companies in Solna, Sweden
The 40 best Life Sciences companies in Solna, Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BioLipox.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Solna
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BioLipox Arachidonic acid based drugs for treatment of Asthma, COPD, Rhinitis, Arthritis | $69M | 259 mo ago | 9 | — | — | — | 232 patents Pharmaceutical compositions for nasal/inflammatory disorder treatment and related formulation processes | — |
| 2 | Affibody Developer of antibody mimetic and protein based drug for the treatment of multiple diseases | $43M | 44 mo ago | 113 | — | WordPressMySQLPHP+18 | Top 10M | 422 patents Therapeutic peptide binders for immune checkpoints and cancer targets | — |
| 3 | Gesynta Pharma Developer of oral therapies for treating chronic inflammatory conditions | $31M | 71 mo ago | 11 | Ralf Morgenstern Co-Founder | UmbracoMicrosoft ASP.NETBootstrap+12 | Top 10M | 25 patents Therapeutic small‑molecule agents for endometriosis and vasoconstriction‑related diseases | — |
| 4 | Scandinavian Biopharma Developer of vaccines for treating diarrhoea | $30M | 78 mo ago | 27 | — | Cart FunctionalityWordPressMySQL+18 | Top 50M | 41 patents Oral recombinant vaccines targeting enterotoxigenic E. coli diarrheal disease using dmLT adjuvant | — |
| 5 | Moleculent Provider of a biology platform that detects cell-cell interactions within their tissue environment | $26M | 4 mo ago | — | Olle Ericsson Founder and CEO | WordPressMySQLRedis+23 | Top 10M | 24 patents In situ nucleic‑acid proximity assay detection and spatial analysis on planar samples | — |
| 6 | Umecrine Cognition Developer of therapeutics for hepatic encephalopathy | $18M | 16 mo ago | 3 | Viktor Drvota CEO | — | — | 117 patents Neurosteroid GABAA‑α3 modulators and their pharmaceutical formulations | — |
| 7 | Dilafor Pharmaceutical company developing heparin derivatives with low anticoagulant activity | $8M | 88 mo ago | 4 | Lena Degling Wikingsson CEO | — | — | 138 patents Heparin-derived anticoagulant therapy for preeclampsia treatment | — |
| 8 | iCellate Cancer profiling tool for precision oncology through liquid biopsy test | $4M | 38 mo ago | 19 | Pelle Redare Entrepreneur & Co-founder | — | — | — | — |
| 9 | Axelar Anti-cancer treatments that target the insulin-like growth factor-1 receptor signalling pathway | $4M | 69 mo ago | 8 | — | — | — | 78 patents Patents concentrated in chemistry & materials | — |
| 10 | Attgeno Developer of intravenous drug to treat acute high blood pressure | $3M | 99 mo ago | 5 | Per Agvald Founder & CEO | — | — | 47 patents Nitrosylated propanediol drugs for treating thromboembolic diseases | — |
| 11 | Thioredoxin Systems Developer of antibiotics against pathogenic bacteria | $2M | 22 mo ago | 5 | Arne Holmgren Founder | — | — | 17 patents Antimicrobial formulations combining silver ions with organoselenium/ebselen compounds | — |
| 12 | APLEX Bio Limited information available | $2M | 53 mo ago | 12 | Umear Naseem Founder & CEO | Wix eCommerceWixSentry+11 | Top 50M | 16 patents Multiplexed biomolecule detection using PCR, padlock probes, and nanomaterial assays | 1 job opening |
| 13 | EMPE Diagnostics POC diagnostic tests for TB | $1M | 42 mo ago | 32 | — | — | — | 10 patents Point‑of‑care nucleic‑acid diagnostic devices with integrated sample preparation. | 1 launch |
| 14 | Kancera Developing small molecule therapeutics for Cancer | $898K | 97 mo ago | 4 | Thomas Olin CEO | WordPressMySQLPHP+11 | Top 10M | 122 patents Design and synthesis of chiral heteroaryl pyrimidine kinase inhibitors for ROR1 and CX3CR1 | — |
| 15 | CARTANA Provider of gene expression mapping technology in brain tissue | $330K | 80 mo ago | 18 | Xiaoyan Qian Co-Founder | — | — | 11 patents Nucleic acid detection and sequencing, focusing on RNA‑templated ligation methods. | — |
| 16 | Genagon Therapeutics Developing antibodies for the treatment of cancer and inflammatory diseases | $233K | 127 mo ago | 10 | Simon Fredriksson Founder & CEO | — | — | 20 patents Targeted peptide therapeutics modulating CLPTM1 and TGF‑β signaling pathways | — |
Top 12 Life Sciences companies in Solna
#1
Series A · Solna, Stockholm County · founded 2019$26Mraised▾
Provider of a biology platform that detects cell-cell interactions within their tissue environment. It offers functional profiling platform that allows scientists to map cell-cell communication directly in clinical tissue, providing insights of the cellular complexity in health and disease.
- May 2026Series A$20M
- Jun 2024Series A$26M
#2
Series A · Solna, Stockholm County · founded 2006 · 3 employees$18.3Mraised▾
Developer of therapeutics for hepatic encephalopathy (HE). Its proprietary platform uses small molecules that inhibit the action of GABA-steroids in the brain. Its lead candidate GR3027 is currently in phase 2a of clinical trials and can be used in both acute life-threatening HE, as well as minimal chronic HE.
- May 2025Grant (prize money)$420K
- Mar 2023Series A$3M
- Sep 2022Series A$3.9M
- Jul 2021Series A$4.1M
#3
Early Stage · Solna, Stockholm County · founded 1994 · 5 employees$2.4Mraised▾
Developer of antibiotics against pathogenic bacteria. The company is developing "EbsArgent" which combines ebselen and silver a synthetic organoselenium drug molecule with antimicrobial activity silver is commonly used as an antibiotic coating on medical devices and wound dressings against pathogenic bacteria.
#4
Series D · Solna, Stockholm County · founded 1998 · 113 employees$43.3Mraised▾
Developer of antibody mimetic and protein based drug for the treatment of multiple diseases. Its proprietary technology platforms are Affibody molecules is used for developing antibody mimetics monoclonal antibodies and antibody fragments. The leading candidate of the company is for prevention of Alzheimers disease, autoimmune diseases, and psoriasis, along with diagnostic imaging program for metastatic breast cancer.
#5
Acquired · Solna, Stockholm County · founded 2000 · 9 employees$68.6Mraised▾
Biolipox researches and develops treatments for respiratory and inflammatory diseases. The Company provides arachidonic acid research and drugs for the treatment of asthma, chronic obstructive pulmonary diseases, rhinitis, and arthritis. In 2007, Biolipox AB was acquired by Orexo. It focuses on arachidonic acid based drugs primarily for the treatment of asthma, COPD, rhinitis, pain, and arthritis. The company’s product portfolio includes (1) NLA Nasal Spray for the treatment of allergic and non-allergic rhinitis (2) Selective PGE2 synthase inhibitor, for the treatment of pain, osteoarthritis, and rheumatoid arthritis (3) Eoxin inhibitor for asthma, COPD, and other inflammatory diseases. It also develops dual effect respiratory drug, a preclinical product for the treatment of asthma and COPD
- Jan 2005Series C$41M
- Jan 2003Series B$22.5M
- Mar 2001Series A$4.5M
- 2000Seed$554.1K
#6
Funding Raised · Solna, Stockholm County · founded 2013 · 27 employees$29.7Mraised▾
Scandinavian develops vaccines for treating diarrhea. It also provides BCG Vaccine AJVaccines contains bacteria of the type Mycobacterium Bovis BCG and is used for protection against tuberculosis.
- Feb 2020Grant (prize money)$11.4M
- Nov 2019Grant (prize money)$3.3M
- Jan 2019Grant (prize money)$8.4M
- Jun 2017Grant (prize money)$3.4M
#7
Series B · Solna, Stockholm County · founded 2017 · 11 employees$31.1Mraised▾
Gesynta Pharma is developing oral therapies for treating chronic inflammatory conditions. The lead candidate of the company GS-248 is used for treating niche inflammatory indications. It's in the preclinical stage. It acts by inhibiting selective mPGES-1(microsomal prostaglandin E-synthase-1).
- Sep 2020Series B$21.7M
- Apr 2019Series A$6.7M
- Mar 2018Series A$2.7M
#8
Series A · Solna, Stockholm County · founded 2011 · 19 employees$4.2Mraised▾
Cancer profiling tool for precision oncology through liquid biopsy test. It offer CellMate a next generation circulating tumor test for the detection of cancer by analysing of blood and saliva samples to healthcare providers and individual consumers.
- Jun 2023Series A$1.8M
- Jul 2021Grant (prize money)$1.2M
- Dec 2019Series A$2.4M
#9
Series A · Solna, Stockholm County · founded 2015 · 32 employees$1.2Mraised▾
EMPE Diagnostics is developing diagnostic solutions for early-stage, point-of-care confirmatory diagnostics for infectious diseases with a special focus on antimicrobial resistance. Its flagship products "miniMDR-TB" allows differentiating single-nucleotide variants of the most common mutations [rpoB 531 (TCG/TTG) and katG 315 (AGC/ACC)] causing MDR-TB. This molecular diagnostic test produces visual signals on lateral flow cassettes corresponding to the respective genotype-tags on lateral flow strips, in less than 60 min. Another product "miniXDR-TB test" allows detection directly either on microscopy positive samples or after considering results from the miniMDR-TB test. It can detect the presence of MTC, katG 315 wt, katG 315 ACC, inhA -15 wt, inhA -15T, rpoB 531 wt, rpoB 531 TTG, rpoB 526 wt, rpoB 526 TAC, gyrA 90 wt, gyrA 90 GTG, gyrA 94 wt, gyrA 94 GGC, rrs 1401 wt,and rrs 1401 G in less than 60 minutes.
- Feb 2023Grant (prize money)$52.9K
- Mar 2021Grant (prize money)$3M
- Mar 2020Grant (prize money)$55.1K
- Dec 2019Grant (prize money)$55.1K
#10
Series A · Solna, Stockholm County · founded 2003 · 4 employees$8.5Mraised▾
Dilafor is a clinical stage biopharmaceutical company that is working on low anticoagulant heparin (LAH) derivatives for indications where heparin is currently not approved due to its anticoagulant activity. The company has one product, Tafoxiparin, under development for treatment and prevention of protracted labor. Tafoxiparin is similar in activity to Fragmin, which is a low molecular weight heparin and the current standard of care for protracted labor, without the anticoagulative properties. Tafoxiparin has been used and shown to be safe in a total of three clinical trials involving 335 subjects of whom 263 were term pregnant women. The results have been encouraging enough for the company to initiate a clinical development program for Tafoxiparin to be used as an adjuvant therapy for women induced into labor and for women in need of labor augmentation due to labor arrest after spontaneous onset of labor.
- Apr 2019Series A$2.5M
- Sep 2016Series A$6M
#11
Deadpooled · Solna, Stockholm County · founded 2003 · 8 employees$3.8Mraised▾
Axelar is developing anti-cancer treatments that target the insulin-like growth factor-1 receptor signalling pathway. The company’s lead drug candidate, AXL1717, is an orally bioavailable small molecule that targets the IGF-1R signalling pathway. The company has completed a randomised, controlled, multicenter, multinational Phase II study on non-small cell lung cancer. The company aims to partner with a pharmaceutical company to complete the clinical program and bring a product to market.
- Nov 2020Seed$3.8M
#12
Seed · Solna, Stockholm County · founded 2020 · 12 employees$1.5Mraised▾
Developer of a hyperplexed molecular detection technology designed for the analysis of numbers of biomarkers both in vitro and in situ. The company's technology utilizes nano and biochemistry to facilitate applications from research to mass-scale in-vitro diagnostics and precision diagnostics, enabling doctors to achieve highly parallelized detection of biomarkers in an easy and cost-efficient way.
- Mar 2022Seed$1.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Sweden
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 299 Sweden-affiliated papers.
- Swedish University of Agricultural Sciences53
- Karolinska Institutet52
- Uppsala University33
- Science for Life Laboratory29
- University of Gothenburg28
- Messenger RNA1→7
- Transcription (linguistics)1→4
- Gene4→5
- Gene1→5
- Antibody1→5
- Antibiotic resistance3
- Antibiotics3
- Agriculture3
- Production (economics)3
- Antimicrobial2
Where biotechnology is researched across Sweden
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.